GLYC stock reacts to reverse split and symbol change

GLYC stock has undergone a reverse split and symbol change to CBIO, reshaping the share count and creating a new ticker reference for investors.

GlycoMimetics stock (ISIN US38000Q1022) has effectively transitioned through a corporate action that includes a 1-for-100 reverse split and a symbol change from GLYC to CBIO, a move that materially alters the share count and trading reference for existing shareholders as of September 5, 2026, according to a corporate actions overview by Robinhood.

Reverse split and new CBIO symbol

According to the corporate actions tracker of Robinhood, GlycoMimetics, Inc. implemented a symbol change from GLYC to CBIO and executed a 1-for-100 reverse split of its shares. This means that for every 100 shares of GLYC previously held, shareholders now hold 1 share of CBIO after the split. The tracker also notes that fractional shares resulting from the split are retained, rather than being cashed out, which has implications for investors with small positions.

For investors, this type of corporate action typically aims to consolidate the share base, often to meet listing requirements or to position the stock for a different valuation range. The effective reduction in outstanding shares by a factor of 100, combined with the new CBIO ticker, changes the way the market will read price levels and market capitalization going forward. While the Robinhood tracker focuses on the mechanics, it highlights that existing GLYC positions have automatically converted into CBIO positions on a one-to-one basis after applying the 1-for-100 ratio.

Implications for existing GLYC shareholders

With a 1-for-100 reverse split, the numerical share count in investor portfolios shrinks sharply, but the proportional ownership in GlycoMimetics remains unchanged at the moment of the split. If an investor previously held 10,000 GLYC shares, this position becomes 100 CBIO shares, while the total value of the position immediately before and after the split is designed to be equivalent, aside from minor execution differences. Fractional shares created by the division, for example when a portfolio did not contain a perfectly divisible number of GLYC shares, are retained, meaning that an investor with 150 GLYC shares would see 1.5 CBIO shares recorded.

From a market perspective, reverse splits often result in a higher absolute trading price, because the pre-split price is multiplied by the split factor, while the outstanding share count falls by the same factor. If GLYC had traded at a hypothetical USD 0.50 per share immediately before the corporate action, the post-split CBIO price would correspondingly be around USD 50.00, assuming no immediate market reaction, while the number of outstanding shares would be one hundredth of the previous total. Even though the Robinhood tracker does not provide real-time price data for CBIO, its description of the split mechanics is consistent with typical reverse split behavior in the equity market.

GlycoMimetics therapeutic focus

GlycoMimetics, Inc. is a biotechnology company that focuses on the development of glycomimetic drug candidates, which are molecules designed to mimic the structure and function of carbohydrates in order to modulate biological processes. The company has historically concentrated on therapies in areas such as hematologic malignancies, leveraging glycomimetic approaches to influence cell trafficking and signaling. Its pipeline has included candidates targeting specific pathways relevant to cancer and other serious diseases, reflecting a high-risk, high-reward profile typical for smaller biotech issuers.

For retail investors, the combination of a complex drug development pipeline and significant corporate actions like reverse splits and ticker changes increases the importance of closely monitoring regulatory filings, clinical trial updates and investor presentations. GlycoMimetics' Investor Relations page provides access to information on past financial results, pipeline status and corporate governance, which helps investors contextualize corporate actions such as the shift from GLYC to CBIO and the 1-for-100 reverse split in a broader strategic framework.

Stock reference and trading view

From a practical standpoint, investors tracking GlycoMimetics stock as of September 5, 2026 need to recognize that the GLYC ticker is no longer the primary trading reference and that CBIO now serves as the symbol following the corporate action described by Robinhood. This transition affects how the stock appears in brokerage accounts, watchlists and charting tools, and it also changes the appearance of historical price and volume data once adjusted for the reverse split. When comparing pre-split GLYC levels with post-split CBIO prices, investors must account for the 1-for-100 factor to obtain meaningful performance measures.

The absence of a new German listing or an explicit DACH trading venue reference in the available sources means that GlycoMimetics remains primarily a U.S.-listed biotech. That said, European investors accessing the stock via international trading platforms will see their GLYC positions recalibrated to CBIO under the same split ratio, and any future market data pages will reflect the adjusted share count and price levels. Understanding these mechanics is essential for interpreting portfolio statements and for avoiding misjudgments about apparent price jumps that stem purely from the arithmetic of a reverse split rather than from a fundamental revaluation.

Key data for GlycoMimetics

• Company: GlycoMimetics, Inc.
• ISIN: US38000Q1022
• Ticker: CBIO (post-split symbol; previously GLYC)
• Trading venue: NASDAQ (primary U.S. listing)
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: Not part of a major large-cap index